Outcome of Sleep Rehabilitation in Autistic Children with Sleep Disorders Is Linked to Melatonin Receptor Genes SNPs

Elisabetta Bolognesi1, Alessandra Carta2, Franca Rosa Guerini1

  • 1IRCCS Fondazione Don Carlo Gnocchi ONLUS, Laboratory of Molecular Medicine and Biotechnology, 20148 Milan, Italy.

Insights

Genetic variants in melatonin receptor genes MT1 and MT2 are linked to sleep problems in children with Autism Spectrum Disorder (ASD). These single nucleotide polymorphisms (SNPs) may predict sleep disorder severity and guide tailored treatments.

Area of Science:

  • Genetics and Neuroscience
  • Pediatric Sleep Medicine
  • Autism Spectrum Disorder Research

Background:

  • Autism Spectrum Disorder (ASD) is frequently associated with sleep disturbances, impacting quality of life.
  • Melatonin signaling, regulated by MT1 and MT2 receptors, plays a crucial role in sleep-wake cycles.
  • Understanding the genetic underpinnings of sleep issues in ASD is vital for developing effective interventions.

Purpose of the Study:

  • To investigate the association between single nucleotide polymorphisms (SNPs) in the MT1 and MT2 melatonin receptor genes and Autism Spectrum Disorder (ASD).
  • To determine if these genetic variants correlate with ASD susceptibility, clinical severity, and specific sleep problems.
  • To evaluate the predictive value of these SNPs for treatment outcomes in children with ASD and sleep disturbances.

Main Methods:

  • Genotyping of six SNPs in MT1 and MT2 genes in 139 ASD children, 82 siblings, and 53 healthy controls of Sardinian ancestry.
  • Assessment of sleep problems using the Sleep Disturbance Scale for Children (SDSC).
  • Correlation analysis between SNP genotypes and clinical severity/sleep problem scores (DIMS, DA, SHY), including evaluation of treatment outcomes.

Main Results:

  • The MT2 rs10830963 G allele was more prevalent in ASD children and siblings than controls.
  • SNPs rs2119882 (MT1) and rs1562444 (MT2) were associated with sleep problems like Difficulty in Falling Asleep (DIMS), Daytime Awakenings (DA), and Sleep Habits (SHY).
  • Specific alleles (rs2119882 T, rs1562444 A) correlated with higher severity scores, and homozygous carriers showed less improvement after rehabilitative treatment.

Conclusions:

  • MT1 and MT2 gene variants may serve as predictive genetic markers for sleep disorder severity in children with ASD.
  • These findings suggest a potential genetic basis for sleep disturbances in ASD, influencing treatment response.
  • Personalized rehabilitative strategies targeting sleep issues in ASD could be informed by these genetic insights.

Related Concept Videos

Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
237
Narcolepsy01:07

Narcolepsy

Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
96
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
163
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
163
Understanding Sleep01:11

Understanding Sleep

Sleep, an essential biological state, involves significant reductions in physical activity, sensory awareness, and interaction with the environment. This complex physiological process is primarily regulated by specific brain regions, notably the hypothalamus and pons, which govern the sleep-wake cycle or circadian rhythm.
The circadian rhythm, a nearly 24-hour cycle, is deeply influenced by environmental light cues. Light exposure directly affects the hypothalamus, which in turn regulates...
224
Sleep-Wake Cycles01:24

Sleep-Wake Cycles

Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and  rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.2K